Comparison · NCT00842530-sae
CYD Dengue Vaccine Group vs Control Group: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CYD Dengue Vaccine Group vs Control Group: serious adverse events. Trial comparisons, record NCT00842530-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00842530-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.118 | 0.106 | 0.131 | wilson | |
| Risk in group 2 | 0.132 | 0.115 | 0.151 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0141 | -0.0366 | 0.00732 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.894 | 0.752 | 1.06 | log | |
| Odds ratio, group 1 over group 2 | 0.879 | 0.722 | 1.07 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on CYD Dengue Vaccine Group than on Control Group | 71 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CYD Dengue Vaccine Group | Participants (both Cohort 1 and 2) received 3 injections of the CYD Dengue vaccine, 1 Inj. each at 0, 6, and 12 months. | 315 | 2,666 | EG000 |
| Group 2 | Control Group | Participants (Cohort 1) received rabies vaccine at Month 0 and placebo at 6 and 12 months. Participants (Cohort 2) received placebo at 0, 6, and 12 months. | 176 | 1,331 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data were collected from Day 0 (post-vaccination) up to 13 months Post-Inj. 3 (up to 25 months).
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Dengue Vaccine in Healthy Children
- NCT number
- NCT00842530
- Phases
- PHASE2
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Interventions
- CYD Dengue Vaccine, Inactivated rabies virus vaccine, Placebo
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Results first posted
- 2019-07-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00842530?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00842530-sae